TAMIM BRAISH Process Chemistry

EDUCATION · PhD - Synthetic Organic Chemistry

EXPERIENCE · 1987-2018 Pfizer - Senior Director Process Chemistry, Early and late Development scaleups and outsourcing.

EXPERTISE · Expertise in appropriate Process Development depending on stage of development;  CMC for INDs;  Expert in Pharmaceutical Sciences Due Diligence.  Over 40 scientific publications and presentations.

BIO

Tamim has a PhD in synthetic Organic Chemistry (Phil Fuchs).  He joined Pfizer R&D in 1987 where he started as a process chemist developing commercial routes for Danofloxacin and Trovafloxacin and scaled the chemistry from 1g to several metric tons.  He also worked on many other drug candidates in multiple therapeutic areas which included commercial products such as Sertraline, Zithromax and Geodon.  In 1994 he became the head of the Early Synthesis Group leading 30 scientists who scaled up every preclinical, Phase I and Phase 2 Pfizer candidate nominated for development in the US.  He initiated, developed and established a new outsourcing strategy for GMP API manufacturing for Pfizer’s early candidates with several US and international vendors.  He oversaw the construction and later the supervision of a new state of the art Kilo Lab in Groton, Connecticut.  In 2002 he shifted to full development where he oversaw the transfer of several commercial products to Pfizer Manufacturing facilities in Ireland and Puerto Rico, working closely with the manufacturing division to ensure the chemistry is suitable for their equipment and facilities.  He served on the Editorial Board of OPRD for 8 years and co-edited a book on Process Chemistry and scaleups (Emerging Trends in Process Chemistry, CRC Press 2007).  In 2009, he became responsible for overseeing teams within Pharmaceutical Sciences conducting Due Diligence activities for potential licensing candidates.  These teams included members from Process Chemistry, Analytical, Formulation, Regulatory, and Quality.  His responsibilities included evaluating these assets and determining the scientific and regulatory risks, establishing costs, timelines and assisting patent attorneys in their IP assessments and finally reviewing contracts for each potential Business Development Deal.  Some noteworthy deals include the acquisition of Bind, Anacor and Medivation. After 31 years at Pfizer, he joined BioPharmaWorks bringing expertise in Process Chemistry, small and large scale syntheses, outsourcing and L&D.